Galectin Therapeutics (NASDAQ: GALT) CEO Joel Lewis details 84,000 RSU vesting and multi-day stock sales

Rhea-AI Filing Summary

Galectin Therapeutics Inc. President and CEO Joel Lewis reported several equity transactions in company stock. On January 2, 2026, 84,000 shares of common stock were acquired at $0 per share upon vesting of Restricted Stock Units, and on the same day 18,571 shares were sold at a weighted average price of $4.1968 per share under a pre-arranged Rule 10b5-1 trading plan. Additional sales of 27,731 shares at a weighted average price of $3.9069 on January 5, 2026 and 37,698 shares at a weighted average price of $3.5772 on January 6, 2026 were also reported.

Following these transactions, Lewis directly beneficially owned 832,592 shares of Galectin Therapeutics common stock. The filing also notes 2,000 shares held in an account where he acts as custodian for a minor child under the Uniform Transfers to Minors Act, for which he disclaims beneficial ownership. The transactions involving multiple sale prices are reported using weighted average prices, with detailed breakdowns available on request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEWIS JOEL

(Last) (First) (Middle)

C/O GALECTIN THERAPEUTICS INC.

4960 PEACHTREE INDUSTRIAL BLVD., STE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		M		84,000	A	$0(2)	916,592	D
Common Stock	01/02/2026		S(1)		18,571(1)	D	$4.1968(4)	898,021	D
Common Stock	01/05/2026		S(1)		27,731(1)	D	$3.9069(6)	870,290	D
Common Stock	01/06/2026		S(1)		37,698(1)	D	$3.5772(7)	832,592	D
Common Stock								2,000	I	as USTA custodian for a minor child(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0(2)	01/02/2026		M			84,000(5)	01/01/2026(5)	(5)	Common Stock	84,000	$0	0	D

Explanation of Responses:

1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

2. Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

3. These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.

4. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

6. The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

7. The shares were sold in multiple transactions at prices ranging from $3.36 to $3.79. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

	Jack W. Callicutt, by power of attorney	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did GALT President and CEO Joel Lewis report on this Form 4?

The Form 4 for Galectin Therapeutics Inc. (GALT) reports that President and CEO Joel Lewis had 84,000 Restricted Stock Units convert into common stock on January 2, 2026 at $0 per share, followed by sales of 18,571 shares that day at a weighted average price of $4.1968 per share, 27,731 shares on January 5, 2026 at $3.9069 per share, and 37,698 shares on January 6, 2026 at $3.5772 per share.

Was the GALT CEO’s stock sale done under a Rule 10b5-1 trading plan?

Yes. The filing states that the reported stock sales were made pursuant to a Rule 10b5-1 plan adopted by Joel Lewis on April 17, 2025, which was previously disclosed in Galectin Therapeutics’ Quarterly Report on Form 10-Q filed on August 14, 2025.

How many Galectin Therapeutics (GALT) shares does Joel Lewis own after these transactions?

After the reported transactions, Joel Lewis directly beneficially owned 832,592 shares of Galectin Therapeutics common stock. The report also lists 2,000 shares held in an account where he acts as custodian for a minor child, and he disclaims beneficial ownership of those custodial shares.

What happened to the 84,000 Restricted Stock Units reported in the GALT Form 4?

The Form 4 shows that 84,000 Restricted Stock Units were disposed of upon conversion into 84,000 shares of Galectin Therapeutics common stock on January 2, 2026, at an exercise price of $0, reflecting vesting of those units.

How were the sale prices reported for the GALT insider transactions?

The sale prices are reported as weighted average prices. For example, shares sold at $4.1968, $3.9069, and $3.5772 per share each represent averages for multiple trades within price ranges disclosed in the footnotes, with full per-trade details available upon request to the company, the SEC, or a security holder.

Does Joel Lewis have beneficial ownership of GALT shares held for a minor child?

The report notes 2,000 shares held of record by Joel Lewis as custodian for a minor child under the Uniform Transfers to Minors Act. It states that he disclaims beneficial ownership of these securities and that the filing is not an admission of beneficial ownership for Section 16 or any other purpose.